Classification of stomach cancer by conventional pathological criteria has not helped in the assessment of prognosis of this tumour (Morson et al., 1990 ) and the availability of new markers that could be applied to routinely-processed pathologic material would be of great value. Recent studies have demonstrated that assessment of gene copy number and expression levels of the receptor tyrosine kinase oncogenes encoding the EGF receptor (also known as c-erbB) and c-erbB-2 (also known as HER2 or neu) can offer useful information for the prediction of prognosis in several common human cancers, such as breast cancer and ovarian cancer. In stomach cancer, amplification or overexpression of c-erbB-2 has been reported in 19-40% of cases (Tal et al., 1988; Yokota et al., 1988; Park et al., 1989; Oda et al., 1990; Gutman et al., 1989; Falck & Gullick, 1989; Houldsworth et al., 1990 ) but only one study has so far examined the concordance between level of expression of this oncogene determined by immunohistochemistry in routinely-processed pathology specimens and gene copy number determined by Southern blotting (Houldsworth et al., 1990) . Until recently, antibodies which reliably detect EGF receptor expression in fixed and paraffin-embedded pathological material have not been available, limiting the study of receptor protein expression. Overexpression of EGF receptors has been detected in frozen samples of gastric adenocarcinoma at a frequency of up to 35% in advanced disease (Yasui et al., 1988a; . However, amplification of the EGF receptor gene appears to be uncommon in stomach cancer (Yoshida et al., 1989) . We set out to determine the frequency of EGF receptor and c-erbB-2 gene amplification and rearrangement by Southern blotting, and to survey the expression of each of these protooncogenes by immunohistochemistry in a parallel series of frozen and routinely-fixed paraffin-embedded gastric cancer specimens.
Gastrectomy specimens were examined by a pathologist immediately after resection and samples of cancer (confirmed on frozen section) were excised, snap-frozen in liquid nitrogen and stored below -70'C until required. The remainder of each specimen was then fixed in formalin or Bouin's fixative and processed for embedding in paraffin blocks. Peripheral blood samples were taken from each patient and the white cell fraction kept frozen below -70°C until required.
High molecular weight DNA was extracted from tumour samples and, in 30 out of the total of 40 cases, a paired sample of peripheral blood leucocytes using a Model 340A Nucleic Acid Extractor from Applied Biosystems, EcoRIdigested DNA (10gg) was electrophoresed in 0.8% agarose gels and transferred to Hybond-N filters (Amersham). Hybridisation and washing were carried as recommended by the manufacturer. Hybridisation probes used to detect protooncogene sequences were, for detection of the EGF receptor gene, a 1.8 kb EcoRI purified fragment of p64.1 (Ullrich et al., 1984) and for detection of c-erbB-2, a 3.25 kb HindlII/ KpnI fragment of pSV2erbB-2 which contains the complete cDNA of c-erbB-2 . The blots were stripped and then rehydridised with a 1.8 kb PstI fragment of beta-actin (Cleveland et al., 1980) to control for loading differences between samples.
Signal intensity on autoradiographs was quantitated using an Ultroscan XL laser densitometer (LKB).
Polymerase chain reaction (PCR) amplification and oligonucleotide probing for transmembrane mutations of the c-erbB-2 proto-oncogene was carried out using oligonucleotides and protocols as previously described (Lemoine et al., 1990a) .
To detect c-erbB-2 immunoreactivity in frozen and paraffin sections an affinity-purified preparation of rabbit antibody 21N (Gullick et al., 1987) was used at a concentration of 2.6 jig ml-'. This reagent has been well characterised and widely used for immunohistochemical detection of c-erbB-2 in tissue sections (Gusterson et al., 1988) . To detect EGF receptor immunoreactivity in frozen and paraffin sections an affinity-purified preparation of the rabbit antibody 12E (raised against a synthetic peptide representing residues 1059 to 1072 in the cytoplasmic domain of EGF receptor, Gullick et al., 1985) was used at a concentration of 4 gg ml-', as well as an affinity-purified preparation of the rabbit antibody 14E (raised against a synthetic peptide of residues 1164 to 1176 of EGF receptor, Gullick et al., 1985) (Falck & Gullick, 1989) . Specificity of the antibodies was tested by loss of staining after pre-absorption of antibody with the immunising peptide, and retention of staining after pre-absorption with other non-specific peptides. Overexpression of the growth factor receptor (EGF receptor or c-erbB-2) is defined as staining of tumour cell membranes, often accompanied by cytoplasmic staining. As detailed below, such immunoreactivity was not observed on cell membranes in normal stomach mucosa.
The results of tumour analysis are presented in Tables I  and II . In the normal stomach very faint cytoplasmic immunoreactivity of EGF receptor was observed only in the parietal cells of the gastric glands when using the 12E antibody. With all of the anti-EGF receptor antibodies there was strong staining of the brush border of surface enterocytes of the normal small intestine and in intestinal metaplasia of the stomach (Figure 2b ). Immunoreactivity for c-erbB-2 was not detected in non-neoplastic stomach with the antibody 21N at the concentration used.
In the tumour series, overexpression of the c-erbB-2 growth factor receptor proto-oncogene (recognised as staining of tumour cell membranes) was detected in 26% of all the cases examined in paraffin section, more frequently in the intestinal type (53%) than in diffuse type (8% (Table II) . In four other cases, the c-erbB-2 gene was present in apparently single copy on Southern blot analysis and there was moderate to strong membrane immunoreactivity just in some areas of the tumour sections. Two cases (omitted from Table II for clarity) were not examined by Southern blot, but had focal 21N immunoreactivity (less than 5% of tumour cells positive). The failure to identify immunoreactivity in frozen sections of some tumours in which there was definite positivity in paraffin sections could be due to the patchy nature of overexpression of c-erbB-2 in cases without gene amplification. The sensitivity of immunohistochemical detection of c-erbB-2 overexpression appears to be at least as good in paraffin sections as in frozen sections in this series. However, other authors have shown that, at least in breast cancer, low levels of c-erbB-2 immunoreactivity detectable in frozen material may not survive exposure to fixation and processing for paraffin embedding (Slamon et al., 1989) .
Oligonucleotide probing of PCR-amplified genomic DNA did not detect any evidence of potentially activating mutations in the transmembrane region of the c-erbB-2 oncogenes in 31 cases examined. This is consistent with the absence of this potential mechanism of activation in other human (Lemoine et al., 1990a, b; Hall et al., 1990; Tuzi et al., 1991) .
Overexpression of EGF receptor (recognised as staining of tumour cell membranes often accompanied by cytoplasmic staining) was detected in 18% of gastric cancers examined by immunohistochemistry on paraffin sections and, as for c-erbB-2, was more frequent in intestinal type tumours (27%) than in diffuse type tumours (12%). There was no apparent association with tumour stage or lymph node involvement, nor with tumour site or growth pattern (expanding/infiltrative). Southern blot analysis revealed two cases (cases 4 and 5 illustrated in Figure lb) of EGF receptor gene amplification out of 30 cases analysed, but only in one of these was overexpression demonstrable as uniform (>80% of the tumour positive) membrane immunoreactivity with the 12E and 14E antibodies in frozen and paraffin sections ( Figure  2a) , and the EGFR1 antibody in frozen sections. The explanation for our failure to demonstrate overexpression in the other case is presently unknown. There were seven cases of EGF receptor overexpression in the absence of gene amplification, but in these cases the immunoreactivity was not uniform and some areas of the tumours were completely negative. The immunoreactivity for EGF receptor in these cases was demonstrable with all of the antibodies used in frozen section, but while the EGFR1 and 12E antibodies gave comparable results in the detection of membrane expression, the 14E antibody gave consistently weaker staining and often showed cytoplasmic rather than membrane localisation in the tumour cells. The sensitivity of immunohistochemical detection of EGF receptor overexpression using the 12E antiserum was higher in paraffin sections than in frozen sections of this series of stomach cancers. This is at least partly accounted for by the greater ease of interpretation of EGF receptor immunoreactivity, often accentuated at the figure) shows no immunoreactivity.
(Formalin-fixed, paraffin section stained by avidin-biotinperoxidase complex method, haematoxylin counterstain, x 125). (Yasui et al., 1988a, b) in which they found a low prevalence of overexpression of EGF receptor in early disease (4%) but a much higher occurrence in advanced disease (35%). Another study reported a high prevalence of EGF receptor mRNA expression in malignant vs XU.V adjacent non-malignant stomach (Bennett et al., 1989) . EGF receptor gene amplification appears to be rare in gastric adenocarcinomas, one group reporting only 3% of cases containing additional gene copies (Yoshida et al., 1989; Oda et al., 1990 ). c-erbB-2 is overexpressed in 20% of advanced stomach adenocarcinomas but not in early disease (Yokota et al., 1986; Fukushige et al., 1986; Yokota et al., 1988; Tal; Park et al., 1989; Falck & Gullick, 1989) . It has been reported as more prevalent in tubular adenocarcinomas than in diffuse cancers. Overexpression is generally a consequence of gene amplification but some overexpressing cases may possess a normal gene copy number, and it is intriguing that one group has recently detected overexpression of a protein that binds to the TATA box of the c-erbB-2 promoter in such a case (Kameda et al., 1990) . Unlike breast cancer, where most tumour cells in a positive tumour uniformly overexpress the protein, in stomach cancer the expression can be patchy or very focal (Falck & Gullick, 1989) . This suggests that overexpression may occur later in the progression of stomach cancer than in breast cancer. Gene rearrangement has also been reported at low frequency in gastric cancer (Park et al., 1989) . One study of 260 stomach cancers reported that c-erbB-2-positive cases behaved more aggressively and had worse prognosis than negative cases (Yonemura et al., 1991) .
There is evidence that assessment of EGF receptor and c-erbB-2 abnormalities can be useful indicators of prognosis in some other human cancers. For instance, poor clinical outcome has been correlated with amplification and overexpression of the c-erbB-2/HER-2/neu oncogene in breast cancer and ovarian cancer (Slamon et al., 1989) , and of the c-erbB/EGF receptor oncogene in breast cancer (Sainsbury et al., 1987) . In breast cancer, cases in which there is overexpression of both of these oncogenes have a worse prognosis than those in which only c-erbB-2 or the EGF receptor alone is overexpressed (Harris et al., 1989) .
We conclude that abnormal expression of the EGF receptor and c-erbB-2 proto-oncogene occurs at a significant frequency in gastric cancer, in the presence or apparent absence of gene amplification. We report the application of antipeptide antibodies which reliably detect such overexpression in routinely-fixed and paraffin-embedded pathologic material and which would be suitable for use in the retrospective analysis of archival material. We suggest that this would be a particularly worthwhile exercise for gastric cancer because conventional typing by the Lauren, WHO and other classifications has been largely unhelpful for prediction of prognosis (Morson et al., 1990 ). An analysis of the expression of these proto-oncogenes can now be carried out in a larger retrospective series of gastric cancers for which survival data is available.
